Insulet (NASDAQ:PODD) will post its quarterly earnings results after the market closes on Wednesday, February 21st. Analysts expect Insulet to post earnings of ($0.08) per share for the quarter.
Insulet (NASDAQ PODD) opened at $76.73 on Tuesday. Insulet has a 12 month low of $38.43 and a 12 month high of $78.65. The company has a quick ratio of 4.42, a current ratio of 4.88 and a debt-to-equity ratio of 4.65. The stock has a market cap of $4,464.75, a P/E ratio of -153.46 and a beta of 1.59.
A number of research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Insulet from a “sell” rating to a “hold” rating in a research note on Thursday, February 1st. BidaskClub upgraded shares of Insulet from a “sell” rating to a “hold” rating in a research note on Friday, January 26th. Raymond James Financial upgraded shares of Insulet from a “market perform” rating to an “outperform” rating and set a $80.00 price objective for the company in a research report on Monday, January 8th. UBS Group upgraded shares of Insulet from a “market perform” rating to an “outperform” rating in a research report on Monday, January 8th. Finally, Barclays restated a “buy” rating and set a $78.00 price objective on shares of Insulet in a research report on Wednesday, December 13th. Eight analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $62.53.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/20/insulet-podd-scheduled-to-post-earnings-on-wednesday.html.
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.